Advertisement

Document › Details
PhoreMost Ltd.. (7/8/19). "Press Release: PhoreMost and inStem Enter Structural Biology Alliance". Cambridge.
inStem’s Centre for Chemical Biology and Therapeutics to work with PhoreMost to progress selected targets
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a structural biology focussed collaboration with the Centre for Chemical Biology and Therapeutics (CCBT), Bangalore, India. CCBT at the Institute for Stem Cell Science and Regenerative Medicine (inStem) is funded by the Department of Biotechnology, Government of India,. The aim of the collaboration is the structural visualisation of novel druggable sites across multiple targets, to rapidly advance new therapies.
PhoreMost’s next-generation phenotypic screening platform SITESEEKER® probes the entire proteome in a live cell environment for novel druggable targets, enabling the systematic unmasking of cryptic druggable sites. PhoreMost has built a pipeline of novel targets and early drug discovery programmes using this platform, and the new collaboration will draw on CCBT’s structural and chemical biology expertise to progress selected targets within PhoreMost’s discovery portfolio.
CCBT is a state-of-the-art multidisciplinary effort, which was formed to pioneer innovative approaches to create chemical tools that modulate novel classes of targets. The Centre integrates biochemistry, genetics and cell biology with structural biology, computational chemistry and synthetic chemistry.
Dr Chris Torrance CEO of PhoreMost, said: “Since its inception, PhoreMost’s model has been to forge a new approach to drug discovery, working collaboratively with partners in order to progress new medicines. We are delighted to announce this alliance with the CCBT and inStem, which represents an important milestone for PhoreMost and has enormous potential to rapidly advance new therapies.”
Professor Apurva Sarin, Director, inStem said: "We are very pleased with the partnership forged between Phoremost and the CCBT under Prof. Ashok Venkitaraman's leadership, and look forward to exciting outcomes from this effort."
Professor Satyajit Mayor, Director, NCBS, and former Director, inStem, said: “We are very excited to announce this collaboration with PhoreMost. The ability of PhoreMost’s SITESEEKER platform to identify first-in-class drug targets together with functional peptide ligands is highly complementary to the structural biology capabilities at inStem and the CCBT. We look forward to supporting drug discovery against these targets to progress the next generation of therapeutics.”
Contacts
Media enquiries
Zyme Communications
Katie Odgaard
E-mail: katie.odgaard@zymecommunications.com
Phone: +44 (0)7787 502 947
or
At PhoreMost Ltd
Dr Chris Torrance, CEO
E-mail: chris.torrance@phoremost.com
or
At inStem
Dr Anandi Karumbati
E-mail: anandisk@instem.res.in
Record changed: 2019-07-16 |
Advertisement

More documents for PhoreMost Ltd.
- [1] PhoreMost Ltd.. (11/9/20). "Press Release: PhoreMost and Oxford Biomedica Enter Gene Therapy Discovery Collaboration". Cambridge & Oxford....
- [2] PhoreMost Ltd.. (9/8/20). "Press Release: PhoreMost and XtalPi Sign AI-based Pharmaceutical drug Discovery Collaboration Agreement". Cambridge & Cambridge, MA....
- [3] PhoreMost Ltd.. (1/7/20). "Press Release: PhoreMost and Boehringer Ingelheim Enter Multi-project Drug Discovery Collaboration". Cambridge....
- [4] Ligand Pharmaceuticals Inc.. (6/12/19). "Press Release: Ligand Subsidiary Vernalis and PhoreMost Limited Announce Drug Discovery Collaboration for Novel Oncology". San Diego, CA & Cambridge....
- [5] PhoreMost Ltd.. (6/21/18). "Press Release: PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery Programs". Cambridge....
- [6] PhoreMost Ltd.. (5/15/18). "Press Release: PhoreMost Completes $15M (£11M) Series A Round to Enter Drug Discovery". Cambridge....
- [7] NeoPhore Ltd.. (4/11/18). "Press Release: NeoPhore Appoints Jeffrey Roix as Chief Executive Officer"....
- [8] PhoreMost Ltd.. (10/12/16). "Press Release: PhoreMost Ltd and University of Cambridge Collaborate to Identify Innovative Drug Targets for Neurodegenerative Disease". Cambridge....
- [9] PhoreMost Ltd.. (3/10/16). "Press Release: PhoreMost and The Wistar Institute Collaborate to Identify New Druggable Targets in Cancer, Immunotherapy and Aging". Cambridge....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top